Preclinical Pharmacokinetic Studies of the Tritium Labelled D-Enantiomeric Peptide D3 Developed for the Treatment of Alzheimer’s Disease

Nan Jiang1, Leonie H. E. Leithold1, Julia Post1, Tamar Ziehm1, Jörg Mauler2, Lothar Gremer1, Markus Cremer3, Elena Schartmann1, N. Jon Shah2, Janine Kutzsche1, Karl-Josef Langen2,4, Jörg Breitkreutz5, Dieter Willbold1,6*, Antje Willuweit2*

1 Structural Biochemistry, Institute of Complex Systems (ICS-6), Forschungszentrum Jülich GmbH, Jülich, Germany, 2 Medical Imaging Physics, Institute of Neuroscience and Medicine (INM-4), Forschungszentrum Jülich GmbH, Jülich, Germany, 3 Structural and functional organisation of the brain, Institute of Neuroscience and Medicine (INM-1), Forschungszentrum Jülich GmbH, Jülich, Germany, 4 Department of Nuclear Medicine, Universitätssklinikum der RWTH Aachen, Aachen, Germany, 5 Institute of Pharmaceutics and Biopharmaceutics, Heinrich-Heine-Universität Düsseldorf, Düsseldorf, Germany, 6 Institut für Physikalische Biologie, Heinrich-Heine-Universität Düsseldorf, Düsseldorf, Germany

* D.Willbold@fz-juelich.de (DW); A.Willuweit@fz-juelich.de (AW)

Abstract

Targeting toxic amyloid beta (Aβ) oligomers is currently a very attractive drug development strategy for treatment of Alzheimer’s disease. Using mirror-image phage display against Aβ1-42, we have previously identified the fully D-enantiomeric peptide D3, which is able to eliminate Aβ oligomers and has proven therapeutic potential in transgenic Alzheimer’s disease animal models. However, there is little information on the pharmacokinetic behaviour of D-enantiomeric peptides in general. Therefore, we conducted experiments with the tritium labelled D-peptide D3 (³H-D3) in mice with different administration routes to study its distribution in liver, kidney, brain, plasma and gastrointestinal tract, as well as its bioavailability by i.p. and p.o. administration. In addition, we investigated the metabolic stability in liver microsomes, mouse plasma, brain, liver and kidney homogenates, and estimated the plasma protein binding. Based on its high stability and long biological half-life, our pharmacokinetic results support the therapeutic potential of D-peptides in general, with D3 being a new promising drug candidate for Alzheimer’s disease treatment.

Introduction

After the initial description by Alois Alzheimer in 1906 [1], Alzheimer’s disease (AD), a progressive neurodegenerative disorder, has become nowadays the most common form (60–80%) of dementia [2]. According to the World Alzheimer Report 2014, nearly 36 million people worldwide are suffering from AD or related dementia. Even after years of intensive
investigation and research, it is still an incurable disease [3]. Current treatments are only supportive against some of its symptoms. Clinical duration of AD varies from one to 25 years, typically eight to ten years [4].

Amyloid beta (Aβ) is produced by sequential cleavage of a type I integral transmembrane protein, called amyloid precursor protein (APP) by β- and γ-secretases. Variable lengths of Aβ isomers differing at the C-terminus are produced due to imprecise cleavage by γ-secretase [5, 6]. The most abundant isomers are Aβ1–40 (approximately 80–90%) and Aβ1–42 (approximately 5–10%). Aβ1–42 is more hydrophobic and fibrillogenic, and therefore the main component of Aβ plaques in the brain of AD patients [7]. It also aggregates readily into oligomers, which are considered to be the most toxic form of Aβ [8–10].

In recent years, many substances have been developed targeting Aβ production and clearance [11], including peptide-based drugs [12, 13]. In spite of the many advantages of peptide drugs, for example high specificity and low toxicity, their short half-life time in vivo due to rapid degradation by proteases, and low bioavailability by oral administration, restrict their clinical usage. In comparison to naturally occurring L-form peptides, peptides derived from partial D-amino acid substitutions or D-enantiomeric peptides, which are composed entirely of D-amino acids, have advantages over L-enantiomers. Because of the stereoisomeric selectivity of proteolytic enzymes they are less prone to proteolysis, therefore longer half-lives and higher bioavailability after oral administration are to be expected [14–16]. Furthermore, they are less or even not immunogenic at all [13].

The fully D-enantiomeric peptide D3, which was identified by mirror-image phage display [17, 18] for binding to Aβ (1–42), has been shown to have interesting properties. D3 inhibits Aβ fibril formation and eliminates Aβ-oligomers in vitro. Ex vivo, D3 has been shown to specifically bind to amyloid plaques in transgenic mice [19]. In vivo, D3 was able to reduce plaque load and inflammation markers in the brains of treated transgenic mice, as well as improve their cognition even after oral administration [20–23]. Here we investigate the pharmacokinetic properties of D3 in mice.

We present the first comprehensive preclinical pharmacokinetic study of a peptide consisting solely of D-enantiomeric amino acid residues in general and in particular for such a D-peptide developed for the treatment of Alzheimer's disease.

Materials and Methods

Materials

3H-D3 (rprrtr-(4,5-3H-Leu)-hthrnr) and its L-form enantiomer 3H-(L)-D3 (RPRTR-(4,5-3H-Leu)-HTHRNR) were purchased from Quotient Bioresearch (Radiochemicals) Ltd. (Cardiff, United Kingdom) with 10–100 Ci/mmol, 1 mCi/ml and purity >95%.

All chemicals were supplied by Fluka Chemie AG (Buchs, Switzerland), Merck (Darmstadt, Germany), AppliChem (Darmstadt, Germany) and VWR (Darmstadt, Germany) in research grade. Micro-osmotic pumps (model 1007D) were purchased from Alzet DURECT Corporation, (Cupertino, CA, USA).

Animals

Male C57Bl/6 mice (Charles River, Sulzfeld Germany) with an average age of 13 weeks and body weight of 28.5 g were used in this study. For micro-osmotic pump i.p. implantation experiment, 19 months old mice were used with average body weight of 34 g. The mice were hosted in the animal facility of the Forschungszentrum Juelich under standard housing conditions with free access to food and water for at least 2 weeks before experiment. All animal experiments were approved by the Animal Protection Committee of the local government.
Pharmacokinetic studies

Mice were administered with 100 μl radioactive working solution consisting of 5 μCi [3H]-D3 in 5 μl with 95 μl buffer (0.1 M phosphate buffer, pH 8) as a single bolus dose either i.v. (tail vein), i.p. or p.o. (gavaging). In order to achieve the desired total D3 concentration, non-radioactive D3 was added to a concentration of 1 mg/ml (i.v.) or 3 mg/ml (i.p. and p.o.). Doses were selected from previous tolerability studies and were not causing any adverse effects. I.v. injections and i.p micro-osmotic pump implantations were performed under anaesthesia with ketamine/medetomidine per i.p. administration. Antisedan was administered s.c. to reverse the anaesthesia directly after the intervention, which took about 10 min. Sampling times were chosen depending on the route of administration (i.p.: 10, 20, 30, 60, 120, 240, 360, 1440 and 2880 min.; p.o.: 10, 20, 30, 60, 120, 240, 360, 1080, 1440, 2880 and 4320 min.; i.v.: 3, 5, 10, 15, 30, 60, 240, 1440 and 2880 min.; 3 animals per time point). For i.p. micro-osmotic pump implantation, delivery dose of pumps was set to 5 μCi [3H]-D3 plus 0.3 mg non-radioactive D3 per 24 hours per mouse. Sampling times were 2, 4 and 6 days after implantation (3 mice per time point).

Upon sampling time, blood was drawn per heart puncture under isoflurane anaesthesia and heparinized plasma was isolated. A small piece of liver (approx. 0.2 g), the left kidney and the right brain hemisphere were sampled. To study the gastrointestinal absorption and elimination by p.o. administration, mice were fasted 18 hours before the experiment and their complete gastrointestinal tracts were prepared. Small intestine was dissected into 4 equal parts and marked from oral to aboral as 1 to 4, respectively. Organ samples were weighted and homogenized in homogenizer tubes (Precellys Ceramic Kit 1.4 mm, Precellys 24, Bertin technologies SAS, Montigny le Bretonneux, France) with 500 μl PBS. 10 ml scintillation cocktail (Ultima Gold XR, PerkinElmer, Waltham, Massachusetts, USA) was added to 100 μl of each organ homogenate or plasma (diluted 1:1 with PBS) and mixed well. Disintegrations per unit time (dpm) were obtained in triplicates with a liquid scintillation counter (Packard Tri-Carb 2100TR Liquid Scintillation Analyser, PerkinElmer, Waltham, MA, USA). Blank values of each sample were obtained by omitting radioactive substance following the same protocol.

Radioactivity counted in each sample was adjusted (subtraction of the blank value) and was expressed as percentage injected dose per gram tissue or millilitre plasma (%ID/g or %ID/ml), or as milligram of total D3 per gram tissue or millilitre plasma (mg/g or mg/ml).

Pharmacokinetic analysis

Pharmacokinetic parameters were calculated with non-compartmental analysis using Phoenix WinNonlin, version 6.3 (Pharsight Corp., St. Louis, USA). Mean D3 concentrations per time point were used to calculate the PK parameters (model type: plasma (200–202); calculation method: linear trapezoidal linear interpolation; dose options: “IV Bolus” for i.v. or “Extravascular” for i.p. and p.o. administration). The same model setting was used to estimate pharmacokinetic parameters of brain. For i.v. administration, plasma concentration at time zero (C0) was back extrapolated with a log-linear regression of the first two observed plasma concentrations, while brain C0 was set to be zero. For the i.p. and p.o. administrations, all concentrations at time zero were set to be zero.
The last three to five observed mean plasma concentrations were used to estimate the first order rate constant in the terminal elimination phase (\(\lambda_z\)) based on the largest adjusted square of the correlation coefficient (R^2) of the log-linear regression lines. The area under the curve (AUC) from C0 extrapolated to infinity (AUC\(_{C0-inf}\)) was calculated as the sum of AUC\(_{C0-last}\) + (Clast/\(\lambda_z\)), calculated from the last determined concentration derived by \(\lambda_z\), and AUC\(_{C0-last}\) representing the AUC from time point zero to the last observed concentration (Clast). Parameters that do not require \(\lambda_z\) were calculated for brain data: time of maximal observed concentration (Tmax), maximal observed concentration (Cmax), maximal observed concentration normalized to dose (Cmax/D), AUC\(_{C0-last}\) and mean residence time from the time of dosing to the last time point (MRT\(_{C0-last}\)). Additional parameters requiring estimated \(\lambda_z\) were calculated for plasma data: \(\lambda_z\), terminal half-life (HL\(_{\lambda_z}\)), AUC\(_{C0-inf}\), terminal volume of distribution (Vz), plasma clearance (Cl), MRT\(_{C0-inf}\) and volume of distribution at steady state (Vss). Absolute bioavailability of i.p. and p.o. administration was calculated with AUC\(_{C0-inf}\) by: F(bioavailability) = [AUC(non-iv)*Dose(iv)/[AUC(iv)*Dose(non-iv)]]*100.

To minimize the time dependence of brain-plasma ratio by bolus dosing, brain-plasma ratio was calculated from the areas under the brain and plasma concentration curves in the terminal elimination phase starting from 4 hours to infinity (brain_AUC\(_{4h-inf}\)/plasma_AUC\(_{4h-inf}\)).

### Plasma protein binding

Plasma protein binding was estimated by incubation of D3 with varying concentrations of protein using TRANSIL\(^{XL}\) binding kits (Sovicell GmbH, Leipzig, Germany). \(K_D\) values were determined by titrating a constant drug concentration against different concentrations of human serum albumin (HSA) and \(\alpha_1\)-acid glycoprotein (AGP). Experiments were performed as recommended for the kit. To obtain the desired D3 stock solution of 80 \(\mu\)M, non-radioactively labelled D3 was dissolved in PBS and 5%\(^3\)H-labelled D3 solution was added for detection purposes. A final concentration of 5 \(\mu\)M D3 was applied in the assay. After incubation and centrifugation 15 \(\mu\)l supernatant were taken and scintillation cocktail was added. This was done in triplicate. Radioactivity was then quantified using liquid scintillation counting. After measuring the disintegrations per minute (dpm) of the supernatant containing the unbound peptide, the D3 fraction bound to the titrated protein was calculated and plotted against the protein concentrations. The curves were fitted to the Michaelis Menten ligand binding equation (SigmaPlot 11.0, Systat Software, Inc., San Jose, California, USA) to obtain the \(K_D\). Mean and relative standard error (%) of multiple measurements are given (AGP n = 3, HSA n = 2).

For bioavailability determination, the unbound fraction of D3 (\(f_u\)) was calculated using the equation below:

\[
f_u = 100 \cdot \frac{C_{D3} - K_D \cdot C_{physiol}}{2} + \sqrt{\frac{K_D \cdot C_{D3} + \left(\frac{C_{D3} - K_D \cdot C_{physiol}}{2}\right)^2}{C_{D3}}}
\]

(1)

For very low D3 concentrations in blood (\(C_{D3}\)), Eq (1) can be simplified by Eq (2), where the unbound fraction of D3 can be calculated independently of the applied D3 concentration. Since this is true for our in vivo experiments we used Eq (2) for the total free fraction of D3, combining the binding of D3 to HSA and AGP. For calculation of the overall unbound fraction according to Eq (2), physiological concentrations (C\(_{physiol}\)) of 0.65 mM HSA and 0.02 mM
AGP were assumed.

\[ f_{u,\text{total}} = 100 \times \frac{1}{1 + \frac{C_{\text{physiolHSA}}}{K_{D\text{HSA}}} + \frac{C_{\text{physiolAGP}}}{K_{D\text{AGP}}}} \]  

(2)

Calibration curves and internal standard

Calibration curves were prepared by adding a corresponding \(^3\)H-D3 dilution series with certain dpm range to plasma or organ homogenates in comparison to those diluted in PBS. The dpm ranges of each \(^3\)H-D3 dilution series were set to cover the measured dpm ranges of each sample (for plasma 400–40000; for brain 100–1200; for liver 3000–15000; for kidney 40000–400000). Plasma and organ homogenates obtained from C57Bl/6 mice were prepared following the same procedure as outlined above.

No differences were found comparing the calibration curves of \(^3\)H-D3 in organ homogenates or plasma to those in PBS. The measured dpm values of the internal standard with \(^3\)H-D3 in PBS matched closely the expected ones.

Thin layer chromatography

In order to study the proteolytic stability of peptides in biological extracts, tritium labelled peptides were incubated with liver microsomes (pooled from mouse (CD-1), Sigma-Aldrich), freshly prepared mouse plasma or extracts of brain, liver and kidney at 37°C for different time periods (from 0 min to 2 days). \(1 \mu\text{Ci}\) (approx. 0.08–0.8 \(\mu\text{g}\)) radioactive labelled peptide was mixed with 1 \(\mu\text{l}\) microsomes stock solution, plasma or organ extracts, respectively (in great excess to peptide). Mixtures containing tritium-labelled peptides were applied onto HPTLC Silica Gel 60 plates (OMNILAB, Essen, Germany) for thin layer chromatography (TLC) with a mobile solvent (2-Butanol/Pyridine/Ammonia(28%)/Water(39/34/10/26)). After development, a phosphor imaging plate for \(^3\)H-autoradiography (FUJIFILM, Tokyo, Japan) was exposed to the TLC plates for 3 days. Images were acquired with a BAS reader and AIDA software (Raytest, Freiburg, Germany). Retardation factor (Rf) of each substance was defined as the ratio of the migration distance of the centre of a separated spot to the migration distance of the solvent front.

Results

Proteolytic stability of D3 in comparison to its L-enantiomer

Before meaningful pharmacokinetic studies could be performed with \(^3\)H-D3, it was essential to show that the D-peptide is stable under near in vivo conditions. First, we compared the stability of \(^3\)H-D3 with its exact enantiomer, \(^3\)H-(L)-D3 in plasma (Fig 1). \(^3\)H-(L)-D3 shows significant degradation already after 60 min incubation in plasma as concluded by the appearance of additional bands as compared to the mixture at 0 min on the TLC plate after detection by autoradiography. In contrast, \(^3\)H-D3 did not show any degradation products even after 2 d incubation in the same plasma preparation.

More importantly, \(^3\)H-D3, was neither degraded after 2 h incubation in liver microsomes nor after 2 days incubation in homogenates of kidney, brain and liver as shown by TLC and detection by autoradiography (Fig 2). Microsomes were checked for proteolytic activity using L-peptide substrates.

Due to high but unspecific affinity of D3 and (L)-D3 to the TLC plate support material (glass), artefacts were observed at the starting points of the TLC as well as light smears.
Pharmacokinetic Study of the D-Peptide D3

Fig 1. Autoradiogram demonstrating proteolytic stability of $^3$H labelled peptides in plasma. $^3$H-D3 was incubated with plasma for different times at 37°C and developed on TLC plates. For comparison, the exact enantiomer of D3, (L)-D3, was used in this stability assay. $^3$H-(L)-D3 was incubated with plasma for 0 and 60 min at 37°C. Please note that free $^3$H-(L)-D3 and free $^3$H-D3 are perfect enantiomers to each other and because the TLC material is not chiral, both compounds show identical RF values. Additional bands in the 0 min lanes of $^3$H-(L)-D3 and $^3$H-D3 that arise from binding and co-migration of $^3$H-D3 and $^3$H-(L)-D3 to plasma components do not necessarily have identical RF values in the 0 min lanes of $^3$H-(L)-D3 and $^3$H-D3, because some of the plasma components are enantiomers themselves. Therefore, any effect of degradation will lead to extra additional bands as compared to the 0 min lane of the very same compound. Obvious proteolytic degradation can be observed for $^3$H-(L)-D3 already after 60 min incubation with plasma leading to additionally appearing bands (black arrows) as compared to the 0 min lane $^3$H-(L)-D3. Additionally appearing bands as compared to 0 min incubation are not observed for $^3$H-D3 even after 2 days incubation.

doi:10.1371/journal.pone.0128553.g001

Pharmacokinetics

Time dependent distribution of D3 in organs and plasma after different administration routes was analysed using tritium labelled D3 ($^3$H-D3) as shown in Fig 4. The corresponding pharmacokinetic parameters calculated with non-compartmental analysis based on the absolute amount of administered D3 are shown in Tables 1 and 2.

After i.v. and i.p. administration, pharmacokinetic curves showed similar patterns with highest concentration of tritium per gram tissue found in kidney, followed by liver and plasma.
However, after oral administration, $^3$H-D3 concentrations measured in kidney and liver did not exceed concentrations in plasma (Fig 4). Plasma Cmax/D after i.v. administration reached 78 μg/ml/mg at Tmax 3 min (the first sampling time point), while after i.p. and p.o. administration plasma Cmax/D were 47 μg/ml/mg at 10 min and 1.5 μg/ml/mg at 240 min (Table 1). In brain, the Cmax/D and their corresponding Tmax values for i.v., i.p. and p.o. administration were 2.8, 2.2 and 1.3 μg/ml/mg at 3, 20 and 240 min, respectively (Table 2). However, after 4 hours concentrations in brain reached similar concentrations irrespectively of the administration route (Fig 4). Although plasma concentrations after p.o. administration appeared to be very low in comparison to i.v. and i.p. administration, comparable concentrations of $^3$H-D3 were found in the brain resulting in high brain/plasma ratio after 4 h (Fig 5).

4 hours after a $^3$H-D3 bolus dose, brain/plasma ratio of all administration routes reached a plateau between 0.7 and 1.0 (Fig 5). To minimize the time dependence of brain/plasma ratio, the absolute ratios were calculated from the area under the brain and plasma concentration.

Fig 2. Autoradiogram demonstrating proteolytic stability of $^3$H labelled peptides in liver microsomes and organ homogenates. $^3$H-D3 was incubated with kidney, brain and liver homogenate for 0, 10, 30, 60, 240 min and 1, 2 days at 37°C and developed on TLC plates. For liver microsomes, the incubation time was 0, 10, 30, 60 and 120 min. Slight difference in Rf values of $^3$H-D3 in liver homogenate might be due to incompletely homogenized liver tissues, which was not observed after incubation with liver microsomes. (Two autoradiograms of liver homogenate were presented in one image and separated through a dashed line.) No obvious proteolytic degradation of D3 can be observed in all the organ homogenates with up to two days' incubation.

doi:10.1371/journal.pone.0128553.g002
curves from 4 hours to infinity (brain_AUC4h-inf/plasma_AUC4h-inf) with 1.07 for i.v., 0.69 for i.p., and 0.85 for p.o. administration.

After bolus administration, D3 showed relatively long elimination half-lives in plasma of 31.8 h, 41.2 h and 40.7 h after i.v., i.p. and p.o. administration, respectively. Plasma clearance was 0.12 ml/min after i.v. administration. Apparent volumes of distribution were different among i.v., i.p. and p.o. administration with 316, 444 and 684 ml, respectively (Table 1).

Absolute bioavailability was high with 92.2% after i.p. administration and 58.3% after p.o. administration (Table 1). When studying gastrointestinal distribution of D3 after p.o. administration (Fig 6), most of the radioactivity was found in the lower intestinal tract after 4 hours, which suggested that the majority of D3 did not enter the system circulation within 4 hours. Still, the AUC of D3 in brain after p.o. administration was comparable to those after i.p. and i.v. administration (Table 2).

We were also interested in answering the question, whether continuous dosing over several days using an i.p. implanted osmotic pump is showing specific effects in D3 distribution. We found linearly increasing D3 concentrations in plasma and all tested organs over 6 days (Fig 7). Although D3 highly accumulated in liver and kidney at day 6, the mice did not show any obvious signs of intoxication. The brain/plasma ratio increased with time from 0.53 at day 2 to 0.77 at day 6.

**Plasma protein binding of D3**

To estimate the free fraction of D3 in plasma *in vivo* (f_u,total), D3 was incubated with human serum albumin (HSA) and α1-acid glycoprotein (AGP) in an *in vitro* assay (Fig 8). The plasma
protein binding assay for AGP resulted in a $K_D$ of 1.8 $\mu$M ± 7.9%. Assuming a D3 concentration in blood of 0.1 $\mu$M ($C_{D3}$, measured 4 h after i.p. injection) calculation of binding to AGP according to Eq (1) predicts a free fraction of 8.3%. For HSA, the $K_D$ was above the detection limit of the kit (> 1.4 mM) indicating very low affinity of D3 to HSA. Nevertheless, calculation of the free fraction with an assumed $K_D$ of 1.4 mM resulted in 68.3% free D3. Taken together, using Eq (2), the estimated free fraction of D3 in plasma was calculated to be approximately 8%.

**Discussion**

In the current study we have analysed the distribution of the D-enantiomeric peptide D3 after single intravenous, intraperitoneal and per oral administration, as well as continuous dosing
via intraperitoneally implanted osmotic pumps. To the best of our knowledge, this is the first report of a comprehensive pharmacokinetic study of a peptide consisting solely of D-enantiomeric amino acid residues in rodents demonstrating excellent proteolytic stability, long plasma half-life and very high oral bioavailability.

D3 showed high proteolytic resistance exactly as it was shown in vitro previously with other all-D-peptides [14–16]. Thanks to this stability, metabolites can be neglected and the measured $^3$H radioactivity represents the concentration of D3 after administration in vivo.

Estimated terminal plasma half-lives of D3 were between 32 and 41 h and were thus much higher than those reported for L-enantiomeric peptides which are typically only a few minutes [25]. Four hours after administration, irrespective of the administration routes, the temporal distribution of D3 in brain closely followed that in plasma resulting in brain/plasma ratios between 0.7 and 1.0 (Fig 5). While substances with a brain/plasma ratio larger than 0.3 are considered to have sufficient access to the central nervous system [26], our results suggest that D3 efficiently overcomes the blood-brain barrier.

Interestingly, by p.o. administration of D3, in spite of only a small rate of D3 being absorbed via the enteric tract, the bioavailability was 58.3% (Table 1), which is relatively high in comparison to that of L-peptide drugs, which were described to be less than 1% without delivery enhancement [27–30]. This finding can be explained by slow oral absorption of D3 and particularly long terminal half-life in plasma resulting in high AUC-values after p.o.

Table 1. Pharmacokinetic parameters for D3 from noncompartmental analysis of plasma.

| Parameter        | Units     | i.v. (3.5 mg/kg) | i.p. (10.5 mg/kg) | p.o. (10.5 mg/kg) |
|------------------|-----------|-----------------|-------------------|------------------|
| Tmax             | min       | 3               | 10                | 240              |
| Cmax             | µg/ml     | 7.75            | 14                | 0.45             |
| Cmax/D           | µg/ml/mg  | 77.5            | 46.7              | 1.48             |
| AUC$_{C0-last}$  | min*$µg/ml$ | 679            | 1763              | 1095             |
| MRT$_{C0-last}$  | min       | 547             | 527               | 1718             |
| Lambda$_z$       | 1/min     | 0.00036         | 0.00028           | 0.00028          |
| HL$_{Lambda_z}$  | min       | 1907            | 2471              | 2439             |
| AUC$_{C0-inf}$   | min*$µg/ml$ | 869            | 2404              | 1521             |
| MRT$_{C0-inf}$   | min       | 1658            | 2104              | 3430             |
| Vz               | ml        | 317             | 445               | 684              |
| Cl               | ml/min    | 0.115           | N.A.              | N.A.             |
| Vss              | ml        | 190             | N.A.              | N.A.             |
| Bioavailability  | %         | 92.2            | N.A.              | 58.3             |

N.A.: Parameters not applicable for this administration route. For abbreviations see methods section.

doi:10.1371/journal.pone.0128553.t001

Table 2. Pharmacokinetic parameters for D3 from noncompartmental analysis of brain.

| Parameter        | Units     | i.v. (3.5 mg/kg) | i.p. (10.5 mg/kg) | p.o. (10.5 mg/kg) |
|------------------|-----------|-----------------|-------------------|------------------|
| Tmax             | min       | 3               | 20                | 240              |
| Cmax             | µg/g      | 0.283           | 0.665             | 0.390            |
| Cmax/D           | µg/g/mg   | 2.83            | 2.22              | 1.30             |
| AUC$_{C0-last}$  | min*$µg/g$ | 275            | 643               | 935              |
| MRT$_{C0-last}$  | min       | 1173            | 1108              | 1693             |

For abbreviations see methods section.

doi:10.1371/journal.pone.0128553.t002
administration (Table 1). Low concentrations of D3 as found in kidney and liver after p.o. administration are desirable because this lowers the risk of possible intoxication of important organs. With absorption enhancers and a more suitable formulation of D3, even higher oral bioavailabilities seem to be feasible. Due to the observed high stability of D3 against proteolysis under biological conditions and its hydrophilic properties, elimination via biliary excretion (without re-absorption) and renal clearance in unchanged form could be expected.

Estimated volumes of distribution were 11.1 (i.v.), 15.6 (i.p.) and 24.0 l/kg (p.o.), respectively considering the body weight of the mice (28.5 g in average). The total body water in C57Bl/6 mice is approximately 0.6 l/kg [31], suggesting a distribution of D3 beyond the body fluid and some uptake in peripheral tissues.

Plasma volume of distribution at steady state was also high with 191 ml and 6.69 l/kg considering the body weight of the mice and the fraction of unbound D3 in plasma was predicted to be around 8%. High volume of distribution promotes low plasma clearance, which in our study was approximately between 0.12–0.19 ml/min observed in all routes of administration.

In summary, the current study demonstrates high proteolytic stability for the D-enantiomeric peptide D3. Furthermore, D3 enters the brain very efficiently and shows high oral bioavailability. The terminal half-life in mice after p.o. administration was approximately 41 hours with a brain/plasma ratio between 0.7 and 1.0, and a bioavailability of about 60%.

**Fig 5. Temporal distribution of brain/plasma ratio of $^3$H-D3 after different administration routes.** Following bolus dose administration, low brain/plasma ratios were found at the starting time points. After 4 hours, the ratios reached relative high values and varied between 0.7–1.0. Upon i.p. pump implantation the ratio increased constantly with time.

doi:10.1371/journal.pone.0128553.g005
Fig 6. Distribution of $^3$H-D3 after p.o. administration in organs and plasma. 20 min after gavaging of 100 μl, 5 μCi $^3$H-D3 with a total D3 concentration of 10.5 mg/kg, most of the radioactivity was located in the middle of small intestine (intestine 2 and 3); 4 hours later, it spread to the lower intestinal tract. Of note is the high concentration of D3 observed in the appendix. At this time point, D3 could already be detected in feces. In comparison to the gastrointestinal tract, the amount of D3 in other organs or plasma after p.o. administration was very low.

doi:10.1371/journal.pone.0128553.g006

Fig 7. Concentration of $^3$H-D3 in kidney, liver, brain and plasma administered via i.p. implanted osmotic pump. Alzet mini pumps with a delivery rate of 0.3 mg D3 (plus 5 μCi $^3$H-D3) per 24 hours were implanted i.p. and organs were sampled after 2 to 6 days. Similar to bolus i.p. administration, more $^3$H-D3 was found in kidney than in liver (A), whereas D3 concentrations in plasma and brain were considerably lower (B). The concentration of D3 was increasing linearly over time suggesting that the saturation concentration in the respective organs and plasma was not reached by 6 days of continuous dosing.

doi:10.1371/journal.pone.0128553.g007
In our previous studies, D3 already proved to be therapeutically active in reversing cognitive deficits and amyloid plaque load \textit{in vivo}. Given its high oral bioavailability, suitably formulated D3 with multiple dosing might be a promising drug candidate against Alzheimer’s disease.

Supplemental Information

S1 File. ARRIVE Checklist. Completed “The ARRIVE Guidelines Checklist” for reporting animal data in this manuscript.

Acknowledgments

We thank Michael Schöneck, Nicole Niemietz and Daniela Schumacher for excellent technical assistance and Dr. Dagmar Jürgens for discussions on the data analysis.

Author Contributions

Conceived and designed the experiments: NJ LL JB LG MC NJS JK KJL DW AW. Performed the experiments: NJ LL JP ES. Analyzed the data: NJ LL JP TZ JM DW AW. Wrote the paper: NJ LL NJS JB DW AW.

References

1. Berchtold NC, Cotman CW. Evolution in the conceptualization of dementia and Alzheimer’s disease: Greco-Roman period to the 1960s. Neurobiology of aging. 1998; 19(3):173–89. Epub 1998/07/14. PMID: 9661992.

2. Fletcher LC, Burke KE, Caine PL, Rinne NL, Braniff CA, Davis HR, et al. Diagnosing Alzheimer’s disease: are we any nearer to useful biomarker-based, non-invasive tests? GMS health technology assessment. 2013; 9:Doc01. Epub 2013/06/12. doi:10.3205/hta000107 PMID: 23755087; PubMed Central PMCID: PMC3677379.

3. Nygaard HB. Current and emerging therapies for Alzheimer’s disease. Clinical therapeutics. 2013; 35 (10):1480–9. Epub 2013/10/22. doi: 10.1016/j.clinthera.2013.09.009 PMID: 24139420.

4. TD B. Alzheimer Disease Overview. 1993. In: GeneReviews(R) [Internet]. University of Washington, Seattle.

5. Mikulca JA, Nguyen V, Gajdosik DA, Teklu SG, Giunta EA, Lessa EA, et al. Potential novel targets for Alzheimer pharmacotherapy: II. Update on secretase inhibitors and related approaches. Journal of clinical pharmacy and therapeutics. 2014; 39(1):25–37. Epub 2013/12/10. doi: 10.1111/jcpt.12112 PMID: 24913554.

Fig 8. The bound D3 (in dpm) over the protein concentration as determined using the TRANSILXL kits. Each sample contained 5 μM D3 added to varying concentrations of AGP or HSA. (A) AGP fitted to the Michaelis Menten equation (red). (B) The binding of D3 to HSA was below the detection limit of the kit (K_D > 1.4 mM). doi:10.1371/journal.pone.0128553.g008
14. Liu M, Li C, Pazgier M, Mao Y, Lv Y, Gu B, et al. D-peptide inhibitors of the p53-MDM2 interaction for Sun N, Funke SA, Willbold D. A Survey of Peptides with Effective Therapeutic Potential in Alzheimer's
13. Zawadzke LE, Berg JM. A Racemic Protein. Journal of the American Chemical Society. 1992; 114
15. Tamaoka A. [The pathophysiology of Alzheimer's disease with special reference to "amyloid cascade hypothesis"]. Rinsho byori The Japanese journal of clinical pathology. 2013; 61(11):1060–9. Epub 2014/01/24. PMID: 24450113.
11. Schenk D, Basi GS, Pangalos MN. Treatment strategies targeting amyloid beta-protein. Cold Spring Harbor perspectives in medicine. 2012; 2(9):a006387. Epub 2012/09/07. doi: 10.1101/cshperspect.a006387. PMID: 22951439; PubMed Central PMCID: PMC3426815.
12. Citron M. Alzheimer's disease: strategies for disease modification. Nature reviews Drug discovery. 2010; 9(5):387–98. doi: 10.1038/nrd2896 PMID: 20431570.
13. Sun N, Funke SA, Willbold D. A Survey of Peptides with Effective Therapeutic Potential in Alzheimer's Disease Rodent Models or in Human Clinical Studies. Mini-Rev Med Chem. 2012; 12(5):388–98. PMID: IS0:000303103600005.
14. Liu M, Li C, Pazgier M, Mao Y, Lv Y, Gu B, et al. D-peptide inhibitors of the p53-MDM2 interaction for targeted molecular therapy of malignant neoplasms. Proceedings of the National Academy of Sciences of the United States of America. 2010; 107(32):14321–6. Epub 2010/07/28. doi: 10.1073/pnas.1008930107 PMID: 20660730; PubMed Central PMCID: PMC2922601.
15. Zawadzke LE, Berg JM. A Racemic Protein. Journal of the American Chemical Society. 1992; 114 (10):4002–3. doi: 10.1021/Ja00036a073 PMID: A1992HT80100073.
16. Milton RCD, Milton SCF, Kent SBH. Total Chemical Synthesis of a D-Enzyme
17. Wiesehan K, Willbold D. Mirror-image phage display: aiming at the mirror. Chembiochem: a European journal of chemical biology. 2003; 4(9):811–5. Epub 2003/09/10. doi: 10.1002/cbic.200300570 PMID: 12964153.
18. Schumacher TN, Mayr LM, Minor DL Jr., Mihollen MA, Burgess MW, Kim PS. Identification of D-peptide ligands through mirror-image phage display. Science. 1996; 271(5257):1854–7. PMID: 8596952.
19. van Groen T, Kadish I, Wiesehan K, Funke SA, Willbold D. In vitro and in vivo staining characteristics of small, fluorescent, Abeta42-binding D-enantiomeric peptides in transgenic AD mouse models. ChemMedChem. 2009; 4(2):276–82. Epub 2008/12/17. doi: 10.1002/cmdc.200800289 PMID: 19072935.
20. van Groen T, Kadish I, Funke SA, Bartnik D, Willbold D. Treatment with D3 reduces amyloid deposits, reduces inflammation, and improves cognition in aged AbetaPP/PS1 double transgenic mice. J Alzheimer's Dis. 2013; 34(3):609–20. Epub 2012/12/29. doi: 10.3233/JAD-121792 PMID: 23271316.
21. van Groen T, Kadish I, Funke A, Bartnik D, Willbold D. Treatment with Abeta42 binding D-amino acid peptides reduce amyloid deposition and inflammation in APP/PS1 double transgenic mice. Advances in protein chemistry and structural biology. 2012: 88:133–52. Epub 2012/07/21. doi: 10.1016/B978-0-12-398314-5.00005-2 PMID: 22814708.
22. Aileen Funke S, van Groen T, Kadish I, Bartnik D, Nagel-Steger L, Brener O, et al. Oral treatment with the d-enantiomeric peptide D3 improves the pathology and behavior of Alzheimer's Disease transgenic mice. ACS chemical neuroscience. 2010; 1(9):639–48. Epub 2010/09/15. doi: 10.1021/cn100057f PMID: 22778851; PubMed Central PMCID: PMC3368690.
23. van Groen T, Wiesehan K, Funke SA, Kadish I, Nagel-Steger L, Willbold D. Reduction of Alzheimer's disease amyloid plaque load in transgenic mice by D3, a D-enantiomeric peptide identified by mirror image phage display. ChemMedChem. 2008; 3(12):1848–52. Epub 2008/11/19. doi: 10.1002/cmdc.200800273 PMID: 19016284.
24. Kilkenney C, Browne WJ, Cuthill IC, Emerson M, Altman DG. Improving Bioscience Research Reporting: The ARRIVE Guidelines for Reporting Animal Research. Plos Biol. 2010; 8(6). ARTN e1000412 doi: 10.1371/journal.pbio.1000412 PMID: IS0002793556000022.
25. Pollaro L, Heinis C. Strategies to prolong the plasma residence time of peptide drugs. MedChemComm. 2010; 1(5):319–24. doi:10.1039/c0md00111b

26. Reichel A. The role of blood-brain barrier studies in the pharmaceutical industry. Current drug metabolism. 2006; 7(2):183–203. Epub 2006/02/14. PMID: 16472107.

27. Wong TW. Design of oral insulin delivery systems. Journal of drug targeting. 2010; 18(2):79–92. Epub 2009/12/09. doi:10.3109/10611860903302815 PMID: 19968567.

28. Takagi H, Hiroi T, Hirose S, Yang L, Takaia F. Rice seed ER-derived protein body as an efficient delivery vehicle for oral tolerogenic peptides. Peptides. 2010; 31(8):1421–5. Epub 2010/05/12. doi:10.1016/j.peptides.2010.04.032 PMID: 20457197.

29. Mason JM. Design and development of peptides and peptide mimetics as antagonists for therapeutic intervention. Future medicinal chemistry. 2010; 2(12):1813–22. Epub 2011/03/25. doi:10.4155/fmc.10.259 PMID: 21428804.

30. Lalatsa A, Garrett NL, Ferrarelli T, Moger J, Schatzlein AG, Uchegbu IF. Delivery of Peptides to the Blood and Brain after Oral Uptake of Quaternary Ammonium Palmitoyl Glycol Chitosan Nanoparticles. Molecular pharmaceutics. 2012; 9(6):1764–74. doi:10.1021/mp300068j PMID: 22263670.

31. Chapman ME, Hu L, Plato CF, Kohan DE. Bioimpedance spectroscopy for the estimation of body fluid volumes in mice. American journal of physiology Renal physiology. 2010; 299(1):F280–3. Epub 2010/05/14. doi:10.1152/ajprenal.00113.2010 PMID: 20462974; PubMed Central PMCID: PMC2904176.